The Great CGT Paradox: Why Billions in New Capacity Could Soon Sit Idle
By 2028, the cell and gene therapy (CGT) landscape may face a crisis of its own making. Projections show that as much as half of the industry’s newly built manufacturing capacity could sit dormant. This isn’t a story of collapsing demand or a sudden freeze in capital. It’s the story of a critical, and widely […]